Progyny, Inc. (NASDAQ: PGNY) is a Healthcare company (Medical - Healthcare Plans) with a market capitalization of $2.7B. The Maz Rating grades it against the other companies in its sector.
Progyny, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $36.71, Progyny, Inc. trades at 31.8x trailing earnings, 2.0x sales and 6.7x book value, with an EV/EBITDA of 18.6. Over the last twelve months it generated about $1.3B of revenue and $85M of net income. It runs a gross margin of 24.9%, an operating margin of 9.4% and a net margin of 6.8%. It shows return on equity of 20.0%, return on invested capital of 19.9% and a free cash flow yield of 8.1%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 1.93. Over the past 52 weeks the share price ranged from $16.10 to $37.21, with a beta of 0.97.
Progyny, Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 15 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.